secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2023-02-01T23:59:59+00:00
Accession:  0001193125-23-021527
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics reports preliminary cash of $114.7M as of Dec 31, 2022
------------------------------------------------------------------------

- Preliminary unaudited cash, cash equivalents and marketable securities total approximately $114.7 million at Dec 31, 2022.
- Quarter-end financial close for Q4 2022 is not yet complete; figure is subject to change upon finalization.
- No additional financial results, revenue, or earnings data were provided in this filing.
- The cash balance excludes any subsequent financing or operating activities through the filing date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312523021527/0001193125-23-021527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312523021527/d413444d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-021527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer